Search for

Volume 7, Issue 5, Pages 502-508 (May 2009)


View previous. 11 of 35 View next.

Continuing Medical EducationTreatment of Chronic Constipation: Current Pharmacologic Approaches and Future Directions

Jan TackCorresponding Author Informationemail address, Stefan Müller–Lissner

published online 15 December 2008.

Refers to article:
Exam 1: Treatment of Chronic Constipation: Current Pharmacological Approaches and Future Directions , 27 February 2009
C. Mel Wilcox
Clinical Gastroenterology and Hepatology
May 2009 (Vol. 7, Issue 5, Pages 495-496)
Full-Text PDF (93 KB)

Chronic constipation is a common condition that affects up to 27% of the population. Dietary and lifestyle measures are usually the first-line therapy, but if these fail to have an effect then a variety of prescription and consumer laxatives are available. Traditional laxatives include bulking agents, osmotic agents, stool softeners, and stimulants of the gastrointestinal tract. All have been found to be more effective than placebo at relieving symptoms of constipation, but these results have been obtained primarily in short (4-week) trials and no class of laxative has been shown to be superior to another. Traditional laxatives work in many, but not all, patients and some patients cannot cope with the side effects, unpleasant taste, the requirements of the dosing regimen, or the notion of dose increase. New enterokinetic agents that affect peristalsis through selective interaction with 5-hydroxytryptamine-4 receptors and novel agents acting on intestinal secretion could offer an alternative option for patients with chronic constipation who cannot get adequate relief from current laxatives.

 Division of Gastroenterology, University Hospital, Leuven, Belgium

 Department of Internal Medicine, Humboldt University, Berlin, Germany

Corresponding Author InformationReprint requests Address requests for reprints to: Jan Tack, PhD, Department of Gastroenterology, University Hospitals Leuven, Herestraat 49, 3000 Leuven, Belgium. fax: (32) 16-344419

 This article has an accompanying continuing medical education activity on page 496. Learning Objectives—Upon completion of this CME examination, successful learners will be able to identify the strength of evidence and mechanism of action of commonly used and future agents for the management of chronic constipation.

 Conflicts of interest The authors disclose the following: Dr Tack is a consultant for Addex Pharma, AGI Therapeutics, Aryx, Astellas, AstraZeneca, Bayer, Chugai, Dainippon Sumimoto Pharma, GSK, Johnson & Johnson, Medtronic, Menarini, Movetis, Novartis, Nycomed, Ocera, Pfizer, Procter and Gamble, Rose Pharma, Smartpill, Solvay, Theravance, Tranzyme, and Zeria; Dr Müller-Lissner is a consultant for Boehringer International, Movetis, Mundipharma, and Procter & Gamble. Writing assistance was provided by Katherine Carpenter and Jude Douglass, and was funded by Movetis NV.

PII: S1542-3565(08)01229-9

doi:10.1016/j.cgh.2008.12.006


View previous. 11 of 35 View next.